Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.

Abstract

Few patients with metastatic triple-negative breast cancer (mTNBC) benefit from immune checkpoint inhibitors (ICI). On the basis of immunotherapy response correlates in other cancers, we evaluated whether high tumor mutational burden (TMB) ≥10 nonsynonymous mutations/megabase and <i>PTEN</i> alterations, defined as nonsynonymous mutations or 1 or 2 copy deletions, were associated with clinical benefit to anti-PD-1/L1 therapy in mTNBC. We identified patients with mTNBC, who consented to targeted DNA sequencing and were treated with ICIs on clinical trials between April 2014 and January 2019 at Dana-Farber Cancer Institute (Boston, MA). Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were correlated with tumor genomic features. Sixty-two women received anti-PD-1/L1 inhibitors alone (23%) or combined with targeted therapy (19%) or chemotherapy (58%). High TMB (18%) was associated with significantly longer PFS (12.5 vs. 3.7 months; <i>P</i> = 0.04), while <i>PTEN</i> alterations (29%) were associated with significantly lower ORR (6% vs. 48%; <i>P</i> = 0.01), shorter PFS (2.3 vs. 6.1 months; <i>P</i> = 0.01), and shorter OS (9.7 vs. 20.5 months; <i>P</i> = 0.02). Multivariate analyses confirmed that these associations were independent of performance status, prior lines of therapy, therapy regimen, and visceral metastases. The survival associations were additionally independent of PD-L1 in patients with known PD-L1 and were not found in mTNBC cohorts treated with chemotherapy (<i>n</i> = 90) and non-ICI regimens (<i>n</i> = 169). Among patients with mTNBC treated with anti-PD-1/L1 therapies, high TMB and <i>PTEN</i> alterations were associated with longer and shorter survival, respectively. These observations warrant validation in larger datasets.